Fusion Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
FUSN Fusion Pharmaceuticals Inc
RDUS Schnitzer Steel Industries Inc
ALEC Alector Inc
LZM Lifezone Metals Ltd
LMRMF Lomiko Metals Inc
SOXL Direxion Daily Semiconductor Bull 3X Shares
OXSQ Oxford Square Capital Corp
BAER Bridger Aerospace Group Holdings Inc
CMRA Comera Life Sciences Holdings Inc
SY So-Young International Inc
Go

Health Care : Biotechnology | Small Cap Value
Based in Canada
Company profile

Fusion Pharmaceuticals Inc. is a clinical-stage oncology company. The Company is focused on developing radiopharmaceuticals as precision medicines. It has developed its Targeted Alpha Therapies (TAT), platform to enable it to connect alpha particle emitting isotopes to various targeting molecules to selectively deliver the alpha particle payloads to tumors. The TAT platform is underpinned by its ability to radiolabel various classes of targeting molecules, its research and insights into the underlying chemistry and biology of alpha emitting radiopharmaceuticals, its differentiated capabilities in target identification, candidate generation, manufacturing and supply chain, its Fast-Clear linker technology used in conjunction with antibody-based targeting molecules, and development of imaging agents. Its clinical portfolio includes FPI-2265, FPI-1434 and FPI-2059. FPI-2265 targeting prostate specific membrane antigen for metastatic castration resistant prostate cancer in a Phase 2 trial.

Price
Delayed
$2.39
Day's Change
-0.155 (-6.09%)
Bid
--
Ask
--
B/A Size
--
Day's High
2.53
Day's Low
2.32
Volume
(Average)

Today's volume of 23,061 shares is on pace to be in-line with FUSN's 10-day average volume of 28,131 shares.

23,061

Intel subsidiary to sell shares of Mobileye in secondary offering; Mobileye stock falls

4:47 pm ET June 5, 2023 (MarketWatch)
Print

Self-driving technology developer Mobileye Global Inc. (MBLY) on Monday said it was launching a secondary offering of 35 million of its shares, which are being sold by Intel Overseas Funding Corp., an Intel Corp. (INTC) subsidiary. Mobileye said it would not receive any proceeds from the sale. Intel plans to give the underwriters a 30-day option to buy up to an extra 5.25 million shares of Mobileye's common stock. Goldman Sachs and Morgan Stanley are working as joint lead book-running managers for the proposed offering. Shares of Mobileye fell 3.6% in after-hours trade on Monday.

-Bill Peters

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.

	

(END) Dow Jones Newswires

June 05, 2023 16:47 ET (20:47 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.